On 28 May 1968, Dr John O’Connell asked the Minister for Health how many children in Ireland had been born damaged by thalidomide, and whether their rehabilitation could be provided free of charge. The Minister, Seán Flanagan, read out what the Medical Research Council of Ireland had found: about 53 children. Dr O’Connell pressed him. This would be a lifelong incapacity, he said. Would the Minister not simply decide that the services should be free?
“I will think about it,” the Minister replied.
The children he was thinking about are now in their sixties. There are roughly 40 of them left in Ireland. Their health is deteriorating in ways that are well documented internationally and barely studied here, and the supports the Irish State provides them still rest on an administrative decision rather than on law. The thinking, in other words, is ongoing.
TL;DR
- Thalidomide was on sale in Ireland between 1959 and 1962. It was withdrawn by its German manufacturer in December 1961, but the Department of Health did not notify doctors and hospitals until July 1962.
- A Medical Research Council survey reported to the Dáil in 1968 found about 53 Irish children with damage attributable to the drug. Today around 40 survivors are living, 29 receive a State payment, and 12 are “unacknowledged” because their mothers took the drug after it was officially withdrawn.
- Survivors are not simply ageing. Sixty years of compensating with the limbs that worked produces a distinct pattern: a UK survey found 93% had musculoskeletal problems, 72% back problems and 49% generalised pain, at a point when fewer than 20% of the general population their age reported any chronic musculoskeletal condition.
- Half reported current or recent depression or anxiety, against roughly 20% of the general population in the same age band.
- Irish survivors do have real entitlements: a medical card regardless of means, monthly payments for life since 1974/5, prophylactic MRI, unlimited hydrotherapy, housing and car adaptations, and a designated HSE liaison manager. All of it is provided “on an administrative basis”.
- The only place the word Thalidomide appears in the Fair Deal legislation is in the list of payments a nursing home may not count as means. The supports themselves are still not in statute, four years after a Minister told the Dáil that work on it was under way.
- German law has offset payments from other governments since 1 August 2013, so an increase in the Irish payment can reduce the German one.
The damage was never only to limbs
Thalidomide was sold as a safe, non-addictive sedative and taken widely for morning sickness. Where it crossed the placenta during a narrow window, roughly 20 to 36 days after conception, it interrupted whichever tissues were forming at that moment.
Shortened or absent arms are the image everyone carries, and upper limb differences did occur in up to 87% of people with thalidomide embryopathy. But the same window caught the eyes, the ears, the vertebral column, the facial nerves and the internal organs. One large UK survey found 31% of respondents reporting internal organ damage, higher than the 22% recorded when they were assessed as children, because scans done decades later kept finding things nobody had looked for. Many have several impairments at once: in that survey, 73 people had upper limb damage and were deaf or partially deaf, and 27 had both sight and hearing impairment.
That matters for a reason that only becomes obvious later. Someone who has spent sixty years working around one impairment has usually been working around three.
What sixty years of compensating does
The Irish Thalidomide Association put it plainly to an Oireachtas committee in February 2022: the late effects are “unplanned, unprecedented, and acutely painful further injuries because of the overuse and misuse of our limbs”.
The clinical picture behind that sentence has been measured, though not in Ireland. A survey of 351 UK survivors, published in PLOS ONE in 2019 when the group was in its mid-fifties, found:
- 93% reported musculoskeletal problems. Back problems 72%, shoulder 60%, hands 59%, arms and wrists 56%, neck 55%, knee 48%, hip 46%.
- The average respondent had 4.5 separate musculoskeletal problems, and more than half had five or more.
- 49% reported generalised pain, and for 26% it was severe or continuous.
- 66% reported at least one neurological symptom such as tingling or numbness.
- Two fifths reported severe tiredness or fatigue.
- Just 3% had no health problem at all, while 46% reported between four and nine separate problems.
- 41% were unable to work because of disability or health problems.
The comparisons are the part worth holding onto. Fewer than 20% of adults aged 45 to 64 in the general population report a chronic musculoskeletal condition, and about 15% report low back pain. In a Scottish study of multimorbidity, fewer than 10% of people aged 55 to 59 had four or more conditions. The thalidomide cohort was running at roughly five times that rate, a decade early.
A 2023 study in the Journal of Hand Surgery (European Volume) surveyed 127 UK survivors with upper limb embryopathy. A quarter reported neuropathic pain, and 70% said their quality of life was deteriorating as they got older. The conclusion was blunt: this group experiences age-related worsening of symptoms and function, and needs ongoing specialist care.
None of this is mysterious. If your left shoulder has done the work of two arms since 1962, it wears out. If your spine has been held at an angle for six decades to bring your hand to your mouth, the discs go. The mechanism is the same one we have written about in post-polio syndrome and in adults ageing with spina bifida: a body that found a workaround in childhood presents the bill in later life.
The half that gets talked about least
In the same UK survey, half of respondents said they were currently or had recently experienced depression or anxiety: 41% anxiety, 34% depression, against around 20% of the general population aged 50 to 54. Even measured against 7,500 physically disabled adults of all ages, where about 19.5% reported depression or mixed depression and anxiety, the thalidomide figure is more than double. It closely matches German survivors, where face-to-face psychiatric assessment found 47.7% with current or recent mental health problems.
It would be easy, and wrong, to file that under “understandable”. Chronic pain, loss of function and the end of paid work are themselves risk factors, and all three arrive together here. Pain that has gone on for years is treatable, and so is the mood that follows it, but only if somebody asks.
Routine medicine stops being routine
The ITA’s opening statement to the Joint Committee on Disability Matters gave one example that says more than a page of policy language. Taking a blood sample.
“Any medical professional person trying to take blood or blood pressure from a person with no arms is faced with an immediate challenge,” Finola Cassidy told the committee. Survivors had been refused blood tests, she said, because staff in a public hospital were “not insured” to take them from the legs. Nerve-ending damage makes the procedure far more painful than it is for anyone else, and decades of childhood medical investigation have left a legacy of fear around it.
The same problem recurs across ordinary care. Blood pressure and body mass index are hard to measure accurately in people with limb differences, which makes the usual cardiovascular risk calculations unreliable just as the age arrives when they matter. A third of UK respondents reported dental problems, linked both to the difficulty of brushing and to a lifetime of using teeth to grip and hold things.
Ireland counted 53, and then stopped counting
On 6 November 1962, nearly a year after thalidomide was withdrawn in West Germany and Britain, the Minister for Health, Seán MacEntee, told the Dáil that he had asked the Medical Research Council to establish how many Irish babies had been affected, that the work was proceeding, and that “present indications are that the size of the problem here is relatively small”.
Asked by Sir Anthony Esmonde whether the victims would be compensated, the Minister replied: “I presume that Deputy Sir Anthony Esmonde, in his question, used the word ‘compensation’ loosely in the sense of making appropriate facilities available and not in its more usual sense.”
That is the whole dispute, in 1962, in one sentence. Sixty-four years later, compensation in its more usual sense is still the outstanding demand.
The survey reported back in 1968: about 53 children. State files released later show why the number is contested. Thalidomide was on sale here between 1959 and 1962. It was withdrawn by Chemie Grünenthal in December 1961, but the Department of Health did not notify doctors and hospitals until July 1962, and a few Irish women went on taking it in pregnancies beginning as late as spring 1962. The departmental defence, recorded in a 1973 memorandum for government: “The suspicions about the drug had not been confirmed and it was not at all obvious that an immediate public statement on the matter should be issued by the department.”
That seven-month gap is not history. It is the live question. The 12 people the ITA describes as unacknowledged survivors are, precisely, those whose mothers took the drug after it had officially been withdrawn. Whether the State accepts them turns on whether it accepts that its own silence kept the tablets in Irish homes.
What an acknowledged survivor actually gets
The supports are real and, in parts, generous. The Department of Children, Disability and Equality published the list in July 2024. Health and social care supports include a medical card, annual assessments, access to allied health professionals, access to international centres of excellence where the expertise does not exist here, prophylactic MRI, and unlimited access to exercise and hydrotherapy facilities. Independent living supports include personal assistant, home support or nursing hours, aids and appliances, car adaptations, housing adaptations, customised clothing, IT solutions and a Free Travel Pass. There is an HSE Thalidomide Advocacy Office and a designated senior HSE manager who liaises with survivors.
Financially, Irish survivors have had monthly payments for life since 1974/5, set on the German Contergan scale, plus a once-off lump sum in 1974/5 set at four times the German lump sum, and further once-off payments in 2010 and 2013. Twenty-nine survivors currently receive the State payment, in a range of roughly €6,175 to €13,313 a year. The payments are exempt from tax and are not assessable as means for social welfare purposes.
Hold that range next to one other figure. The Department of Social Protection’s Cost of Disability report found that the actual additional annual costs faced by individuals with severe disabilities average €9,600 to €12,300. The lifelong payment, in other words, sits roughly where the extra cost of the disability sits. It funds the consequence. It does not answer the question Sir Anthony Esmonde asked in 1962.
The word doing all the work is “administrative”
Read the Minister for Health’s written answer of 12 July 2022 carefully. Irish survivors receive “a medical card on an administrative basis regardless of means”. Then: “Work is under way in the Department to provide these health and personal social supports on a statutory footing as committed to by the Government.”
That sentence has been repeated in ministerial answers for years, and it has not yet happened. Everything on the gov.ie list exists because the State decided to provide it, not because an Act obliges it to. It is a scheme without a statute, administered at departmental discretion, for a group whose needs are rising steeply.
There is one small, telling exception. Search the Fair Deal legislation and the word does appear. Schedule 1, Part 3 of the Nursing Homes Support Scheme Act 2009 defines a “relevant payment” that must be disregarded in a financial assessment, and paragraph (e) covers “an ex-gratia payment or payments made to the person by the Minister or the Conterganstiftung für behinderte Menschen in respect of a disability caused to that person by Thalidomide”.
So Irish law does name thalidomide survivors. It names them to tell the Fair Deal assessment not to count their money, a protection that matters more every year as this cohort nears the age of nursing home assessment. But it is a strange kind of recognition: the State has legislated for what happens to the payment, and not for the payment.
The German offset, and why it matters here
Since 2013 the German Contergan Foundation has accepted applications directly from individuals, and the Irish position, stated in the Dáil, is that any Irish person may apply and that anyone who establishes their injury is attributable to thalidomide will be offered supports commensurate with those provided to acknowledged Irish survivors.
There is a catch, and the Department publishes it. From 1 August 2013, under German legislation, financial payments made by other governments to thalidomide survivors are offset against German payments. An increase from Dublin can be met by a reduction from Germany. That is a real constraint on any Irish settlement, and part of why survivors have been so insistent that what they are owed is an acknowledgement of Irish State responsibility rather than simply a larger cheque.
Where it stands in October 2026
In July 2024 the Government announced the enhanced health package described above, and set up a confidential, judge-led facilitation process under retired judge Paul Gilligan, who has been meeting survivors and is to recommend an ex-gratia payment for each of them.
In October 2025, after the ITA said the process had reached an impasse, the Taoiseach and Tánaiste confirmed that discretionary medical cards would be provided to unacknowledged survivors: those seeking acknowledgement, or intending to seek it, through the State process. In February 2026 a commitment was given that there would be a State apology.
At the most recent public account, after a meeting in early July 2026, the ITA reported “a little bit of headway” on the unacknowledged survivors but remained “still slightly disappointed that they want a lot more done before the apology will happen”. The four asks are unchanged: a State apology, recognition of the unacknowledged survivors, statutory supports, and a fair compensation scheme.
If this is your family
A few practical things, whether you are a survivor, a partner, an adult child or a GP with one of these patients on your list.
New pain is not “just your age”. A new shoulder, neck or back problem in this group usually has a mechanical cause that can be identified and often managed. It deserves imaging and a physiotherapy or orthopaedic opinion, not reassurance.
Use the annual assessment and the liaison manager. Acknowledged survivors are entitled to an annual health assessment, and a designated senior HSE manager exists to help them access supports. Where care is fragmented, that post is the most useful phone number in the system.
Ask about mood, every time. Half this cohort has recent or current depression or anxiety, and it is the thing least likely to come up unprompted in an appointment about a shoulder.
Plan the adaptations before the crisis. Housing and car adaptations are part of the package, and grant-funded work takes months. The time to do a bathroom is while the shoulder still works.
Know the Fair Deal position. Payments from the Minister or from the Contergan Foundation are disregarded in a Fair Deal financial assessment. If an assessment letter suggests otherwise, it is wrong, and the text is in Schedule 1, Part 3 of the 2009 Act.
Forty people, and everyone like them
Forty people is a rounding error in a health service of five million. But the ITA made the better argument themselves, describing their members as a microcosm: disabled people now in their sixties, after a lifetime of barriers, whose needs are rising fast and predictably.
Ireland has several such groups reaching later life together: polio survivors, the first generation screened for PKU, adults with spina bifida or cerebral palsy who were never meant, by the actuarial assumptions of the 1960s, to be here. All share one problem: services designed around childhood, and nothing designed around the decades that followed.
At Críonna Health we keep coming back to the same observation. Growing older with a condition you were born with is not the same as growing older, and it is not the same as living with that condition at 30. It is a third thing, with its own pattern, and it is almost always treated as one of the first two. For Irish thalidomide survivors that gap has an unusually precise measure: fifty-eight years between a Minister saying he would think about making their care free, and a State that still has not written their care into law.
This article is for general information and is not medical advice. If you are living with a lifelong disability and have noticed new pain, weakness or loss of function, speak to your GP and ask for a referral rather than accepting that it is age.
📷 Photo by Enis Yavuz on Unsplash
